A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.